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CASE PRESENTATION
A 67-year-old African American female with end-stage
renal disease secondary to renal artery stenosis and
ischemic nephropathy presents with increased
somnolence of 1-day duration. Past medical history is
notable for depression, mild dementia, glaucoma, gastro-
esophageal reflux disease, Graves disease that is inactive,
diastolic heart failure, atrial fibrillation, and peripheral
vascular disease. Two years prior to admission, the patient
had undergone a dobutamine stress test for the work-up
of dyspnea that was reported normal. The patient had a
left brachio-cephalic arteriovenous graft inserted in
February 2004. In November 2006, 2 months before
the present admission, the graft required a declotting
procedure and angioplasty and stenting of two lesions
in the cephalic vein. At the same time, large
pseudoaneurysms of the mid-venous and mid-arterial
limbs were also identified. Medications included aspirin,
diltiazem, amiodarone, esomeprazole, salmeterol,
sevelamer, paricalcitol, and metoprolol. The patient was
receiving epoetin at each dialysis treatment using an
anemia protocol (10 000 U every dialysis treatment, three
times each week, that had been intensified over the prior
3 months; Figure 1). Approximately 1 month prior to
admission, the patient had received iron gluconate
125 mg 1 dose. Social history was significant for the
patient living at home with a nephew as her principal
caregiver. There was no significant family history. Review
of systems was not possible as patient was too somnolent.
On examination the patient was drowsy. Blood
pressure was 120/70 mm Hg and heart rate was 61 beats
per min. She was afebrile and had normal respiratory
rate. Pupils bilaterally were equal and reactive to light.
Other cranial nerves, motor, and sensory examination was
grossly normal. The examination of other systems was
otherwise unremarkable except for 1þ edema bilaterally
and the absence of a thrill or bruit over the left
brachiocephalic arteriovenous graft. Laboratory testing
on admission revealed a serum sodium of 140 mEq/l,
potassium 5.6 mEq/l, chloride 90 mEq/l, bicarbonate
33 mEq/l, blood urea nitrogen 30 mg/dl, creatinine
5.9 mg/dl, glucose 42 mg/dl. Calcium, phosphate, and liver
function tests, including transaminases and bilirubin, were
within normal limits, except for alkaline phosphatase
of 120 IU and serum albumin, 3 mg/dl (normal range
3–5 mg/dl); hematocrit was 55.9%; hemoglobin (Hgb)
16.8 mg/dl, white blood cell count was 6.42 106 l1
(normal range 4.5–11 106 l1), platelets 219 000.
Her laboratory records from 2 weeks previously, as
checked in her outpatient dialysis unit, showed Hgb
level of 13.1 mg/dl, transferrin saturation of 23%, serum
ferritin level of 283 ng ml1, and serum albumin level
of 3.1 g/dl.
FINAL DIAGNOSIS
(1) Iatrogenic secondary polycythemia with thrombosed left
brachio-cephalic arterio-venous graft.
(2) Somnolence secondary to hypoglycemia/polycythemia.
CLINICAL FOLLOW-UP
The patient was treated with intravenous dextrose with
consequent amelioration of hypoglycemia. Her mental state
improved slightly after treatment with dextrose and she was
admitted for observation and gentle hydration. The left
thrombosed arteriovenous graft could not be declotted
because of the high risk of rupture of one or more of the
pseudoaneurysms. Instead, a hemo-split tunneled dialysis
catheter was inserted into her right internal jugular vein.
Epoetin therapy was discontinued. The patient was dialyzed
and approximately 1 unit of blood was removed to manage
her polycythemia. She became more alert and oriented over
24 h and returned back to baseline. She was discharged 1-day
post admission.
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DISCUSSION
Anemia is present in the vast majority of patients on dialysis.
It reflects a combination of erythropoietin deficiency and
iron deficiency, as well as bone marrow resistance to
erythropoietin. The use of erythropoiesis-stimulating agents,
such as epoetin and iron therapy, has been a boon in the
management of anemia in dialysis patients. However, the case
presented here also highlights some of the challenges in
managing this anemia in the dialysis unit. The patient
presented with a vascular thrombosis that likely reflected an
underlying venous stenosis in her arteriovenous graft. However,
thrombosis could have been precipitated by the very high
hematocrit level and the consequent increase in blood viscosity.
Alternatively, use of higher epoetin dosing might have been the
cause, since, in the normal hematocrit study, patients assigned
to the normal-hematocrit group had a higher incidence of
vascular access thrombosis compared with those in the low-
hematocrit group (39 versus 29%), with clotting of both
synthetic grafts and native fistulae.1 The patient’s hemoglobin
(Hgb) concentration (hematocrit is generally 3 the Hgb level)
increased by 60% over her baseline level or approximately 6 g/dl
over a 6-week period in response to a more intensified epoetin
dosing (from an epoetin dose of 12 000 to 300 000 U week1
over a 12-week period) that reflected the epoetin dosing
protocol for all patients at the dialysis unit. Prior to this abrupt
and rapid upward excursion of Hgb, the patient also
demonstrated variability in her Hgb level, a phenomenon that
has been referred by some authors as Hgb cycling (Figure 1).2 In
this paper we discuss the importance of maintaining patients
within a narrow Hgb range as well as the concepts of Hgb
cycling and Hgb overshoot.
THE TARGET Hgb IN DIALYSIS PATIENTS
A recent Food and Drug Administration (FDA) Black Box
Advisory recommends both targeting and maintenance of the
Hgb levels below 12 g/dl.3,4 This is because several rando-
mized controlled studies have indicated increased risk
associated with higher Hgb levels both in dialysis and in
non-dialysis chronic kidney disease patients.1,5–7 A meta-
analysis concluded that there is a 17% higher risk in
mortality with aiming for the higher Hgb level. The higher
mortality has been attributed to a higher risk of cardiovas-
cular disease (CVD) complications.7 The study most
pertinent to Hgb targets in dialysis patients is the Normal
Hematocrit Study.1 In this study, 1233 high-risk symptomatic
patients were randomized to a target hematocrit of 42%
versus a hematocrit of 30%. An increased risk of death or
myocardial infarction was observed in the higher versus lower
hematocrit group; relative risk, 1.3 (95% confidence interval
0.9, 1.9). Notably, this study was halted because ‘differences
in mortality were recognized as sufficient to make it very
unlikely that continuation of the study would reveal a benefit
of the normal-hematocrit group and the results were nearing
the statistical boundary of a higher mortality rate in the
normal hematocrit group’. More recently, the FDA has posted
an analysis of results from the complete study sample of the
Normal Hematocrit Study rather than the results of the
interim analysis that was published (a study sample size of
1265 instead of 1233).1 The complete study data, reveals that
the ‘log rank test of event-free survival revealed a P-value of
0.01, favoring the low-hematocrit group. The unadjusted
relative risk for a primary end point event was 1.28 (95%
confidence interval of 1.06–1.56) for patients in the high-
hematocrit group compared with those in the low-hematocrit
group’.8
In a double-blind, randomized-controlled trial in 596
incident hemodialysis patients without symptomatic heart
disease and left ventricular dilation, conducted by Parfrey
et al.,9 lower (9.5–11.5 g/dl) and higher (13.5–14.5 g/dl) Hgb
targets were generated with epoetin alpha over 24 weeks and
maintained for an additional 72 weeks. The primary outcome
measure was left-ventricular volume index. The mean Hgb
levels in the higher and lower target groups were 13.3 and
10.9 g/dl, respectively, at 24 weeks. Percentage changes in left-
ventricular volume index between baseline and last value
were similar (7.6% in the higher and 8.3% in the lower target
group) as were the changes in left-ventricular mass index
(16.8 versus 14.2%). For the secondary outcomes, the only
between-group difference was improved SF-36 vitality score
in the higher versus the lower target group. Overall adverse
event rates were similar in both target groups. Thus, from
this study, normalization of Hgb in incident hemodialysis
patients did not show any beneficial effect on cardiac
structure, compared with partial correction. A more recent
study, the Correction of Hemoglobin and Outcomes in Renal
Insufficiency (CHOIR) trial, studied non-dialysis chronic
kidney disease patients and was concordant with the results
of the Normal Hematocrit Study.5 In the CHOIR trial, a 34%
higher risk for death and cardiovascular complications in the
higher Hgb group (achieved mean Hgb of 12.6 g/dl in the
higher Hgb group compared with achieved mean Hgb of
11.3 g/dl in the lower Hgb group; P¼ 0.03) was reported. In
the CHOIR trial, the risk of death was 48% higher for
patients randomized to the higher Hgb group, although
6
7
8
9
10
11
12
13
14
H
em
og
lo
bi
n
15
16
17
18
31 December
31 January
28 Febraury
31 March
30 April
31 May
30 June
31 July
31 August
30 September
31 October
30 November
31 December
21 January
22 January
24 January
Date
0
2000
4000
6000
8000
10 000
12 000
EP
O
 d
os
e 
(U
/di
aly
sis
)
Hemoglobin
EPO (U/Dialysis
Time course of hemoglobin and EPO dosage
Figure 1 | Epoetin dose and Hgb trends in the index patient over
1 year.
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because the study was not powered for death, this difference
did not achieve statistical significance.
Balanced against this increased risk, is the potential benefit
of anemia treatment, namely, better quality of life (QOL) and
a lesser likelihood of requiring transfusions. Reducing the
need for blood transfusions is especially important in
patients who are eligible for kidney transplantation since
exposure to donated blood may increase the risk of
sensitization. While studies have demonstrated an improve-
ment in the QOL with the aim for higher Hgb level, the data
for a benefit in the QOL have been inconsistent in the
11–13 g/dl range, as suggested by the study by Parfrey et al.9
The problems inherent in these studies include selective
reporting of results of various QOL sub-scales, the use of
unvalidated scales, and the non-blinded nature of these
studies. The beneficial effects of QOL improvements also
attenuate over time. Therefore, while aiming for a higher Hgb
appears to be associated with a clear pattern of increased risk,
evidence to support QOL benefits is less compelling.
Hgb CYCLING
Hgb cycling is defined as non-physiological oscillation or
periodic fluctuation in Hgb levels in an individual patient.
The oscillation has arbitrarily been characterized as 41.5 g/dl
from an equilibrium point with reversion back to the same
point over a period of at least 8 weeks.10 Several studies have
assessed the stability of Hgb values over time. More than 90%
of stable hemodialysis patients demonstrate at least one Hgb
cycle.2 The mean number of Hgb cycles was 3.3 per year and
the mean amplitude was 2.5 g/dl, with resulting Hgb level
outside the desired range. In a study by Lacson et al.,11
patients were categorized by Hgb level into three tiers, o11,
11–12, and 412 g/dl in the first quarter of the year. These
Hgb values were tracked during the subsequent three
quarters of the year 2000. Only 8% of patients remained in
the o11 g/dl Hgb tier and, similarly, only 18% remained at
412 g/dl tier for the subsequent quarters of the year. The
study suggested that to maintain at least 90% of patients with
a 3-month rolling average Hgb of more than 10 g/dl, 13 to
31% of patients would overshoot at some time of the
year with 3-month rolling average Hgb levels of more than
12.5 g/dl. In a more recent cross-sectional analysis of Hgb
distribution in hemodialysis patients from the Fresenius
Medical Care-North America database, the 3-month rolling
average of Hgb levels for the whole cohort was 11.6 g/dl.12 Of
these patients, 27% had o11 g/dl, 39% had between 11 and
12 g/dl, and 34% had 412 g/dl. When analyzed over a period
of 2 years, patients with Hgb ranging between 11 and 12 g/dl
remained stable, but a significant reciprocal fluctuation in the
percentage of patients occurred in patients with Hgb values
412 ando11 g/dl. The mean duration of Hgb excursion was
around 5 weeks. These data and other analyses from US
Renal Data System suggest that in most patients the Hgb
concentration in dialysis patients is in a constant state of flux;
however, majority of patients are able to achieve an Hgb
concentration in the 11–12 g/dl range.13 The factors thought
to determine Hgb cycling are listed in Table 1. A change in
epoetin dose appears to be the most important factor
associated with Hgb excursions.2 In one study, the dose of
epoetin was changed an average of 6.1 times per patient per
year (in about 80% of patients), and these authors have
argued that these dose changes are the major driving force in
inducing Hgb cycling.2 Other important factors are recent
hospitalization and initiation of iron therapy. The effect of
hospitalization on an end-stage renal disease patient’s Hgb
level and epoetin requirements was investigated in a retro-
spective chart review of 65 hemodialysis patients hospitalized
for more than 2 days.14 Mean Hgb levels were lower after
discharge than preadmission levels for approximately
2 months despite an increase in epoetin dose. Factors
involved in hospitalization-associated Hgb cycling include
blunted epoetin-responsiveness secondary to induction of
inflammation related cytokines, missed epoetin doses,
changes in epoetin dose, surgical or other invasive procedures
with blood loss, and phlebotomy for laboratory tests. Iron
status was also found to affect Hgb cycling. Intravenous iron
therapy was associated with 27% of rising Hgb excursions.2
After a course of intravenous iron is completed, there
continues to be fluxes in iron status that may last several
months suggesting a complex relationship between intrave-
nous iron dosing and Hgb cycling. In this regard, Hgb and
iron cycling are two interwoven processes that both affect
Hgb concentration and perhaps Hgb cycling. Other less well-
characterized factors that may also influence Hgb cycling
include nutrition status, inflammation, and physician
practice patterns (Table 1).
The impact of Hgb cycling is not clear. Gilbertson et al.
studied 151 118 hemodialysis patients receiving epoetin with
Medicare as primary payer. In their study, 90% of patients
experienced Hgb cycling and these changes were predictive of
mortality risk. Patients with Hgb levels consistently within
Table 1 | Possible causes for Hgb cycling in dialysis patients
1. Patient related
Recent hospitalization
Epoetin responsiveness
Dialysis adequacy
Inflammation
Interdialytic weight gain
Secondary hyperthyroidism
Coincidental chronic infections
Blood loss/hemolysis
2. Practice-pattern related
Alterations in frequency and dose of epoetin
Narrow target Hgb range
Administration of iron therapy
Volume removal at dialysis
Route of epoetin administration
Reimbursement and quality assurance policies
Frequent sampling
Laboratory errors
Hgb, hemoglobin.
Kidney International (2008) 74, 679–683 681
AK Singh et al.: Anemia in dialysis patients t h e r e n a l c o n s u l t
11–12.5 g/dl have the best outcomes. These data suggested
that the longer the time a patient’s Hgb is within the
target range of 11 to 12.5 g/dl, the lower is the risk of
mortality.15
Hgb OVERSHOOT
There is no widely accepted definition of ‘Hgb overshoot’,
although the use of 3 g/dl is reasonable based on evidence This
is different from another phenomenon ‘a rapid rise in Hgb’,
which has been defined by the FDA as a 41 g/dl rise in Hgb
concentration over a 2-week period. In the study by Fishbane
et al.,2 415% of patients had Hgb excursionsX3 g/dl, with a
mean amplitude of upward excursions (rising Hgb) of
2.7±0.9 g/dl over a mean of 10.2±5.8 weeks. The causes of
Hgb overshoot are likely to be similar to those of Hgb cycling.
Indeed, it is argued that this phenomenon may reflect a ‘one-
size fits all’ strategy of protocolizing anemia management
rather than individualizing treatment. Hgb overshoot also
emphasizes plausible wider fluctuation of Hgb levels, the
impact of which could be much worse than the Hgb cycling.
RECONCILING THE FDA ADVISORY AND THE PHENOMENON
OF Hgb CYCLING
In the Black Box warning on the use of epoetin, the FDA
emphasized the importance of maintaining the Hgb level
o12 g/dl. The KDOQI 2007 update on Hgb target addresses
the upper and lower targets. Statement 2.1.2 states that the
Hgb target range should generally be 11–12 g/dl.16,17 If the
word ‘generally’ implies some individualization of therapy,
then this represents a sensible approach. However, because of
the phenomenon of Hgb cycling, targeting an 11–12 g/dl Hgb
range may be quite difficult for some patients; it could be
argued that targeting the 11–12 g/dl range and achieving
levels somewhat higher than this level is acceptable under the
circumstances. Because of the risks associated with higher
Hgb targets, expansion of the target range should not occur
at the upper limit due to the importance of patient safety.
Therefore, aiming for an Hgb range of 10 to 12 g/dl and
achieving an Hgb concentration in the 11–12 g/dl range seems
both prudent and practical. Although randomized studies
examined only two Hgb targets, a higher level in the 13–14 g/dl
range and a lower level in the 10–11.3 g/dl range, with no
intermediate level, a patient-safety orientated interpretation
of the randomized controlled trial (RCT) data support the
conclusion that an Hgb level of 10 to 12 g/dl is appropriate.
This is because it remains unclear whether the increased risk
might also be found with intermediate levels Hgb, that is, in
the 12–13 g/dl range. The increased risk of death observed in
the CHOIR, CREATE, and Normal Hematocrit Cardiac Trial
(21–48% increase with higher Hgb targets) was found with
Hgb targets of greater than 13 g/dl, but with achieved Hgb
concentrations in the 12–13 g/dl range. Since intermediate
Hgb levels were not formally tested (12–13 g/dl), it remains
possible that the full boundary of risk might extend into the
12–13 g/dl target range. Some might argue for a QOL benefit
in the 12–13 g/dl Hgb range, a trade-off between increased
risk and treatment benefit. However, as discussed earlier, this
QOL benefit has been quite inconsistent (the two largest
studies, CHOIR and Normal Hematocrit Study, failing to
find incremental benefit with higher Hgb targets). Until such
time as newer studies provide greater clarity, current
treatment should place patient safety first by avoiding Hgb
targets greater than 12 g/dl.
Hgb VARIABILITY, EPOETIN, AND RISK OF THROMBOSIS
The clinical significance of Hgb variability and overshoot
remains unclear. Some have suggested that Hgb cycling may
be associated with worse outcome due to fluctuation in
oxygen delivery and episodic myocardial ischemia as Hgb
levels oscillate.18 However, since Hgb variability is deter-
mined by many factors, its validity as a surrogate outcome
predictive of poor prognosis remains to be determined, and
will require RCT’s. The patient described here clearly had an
excursion of Hgb that reflected an abrupt overshoot.
Although it is difficult to attribute the thrombosed vascular
access to the high Hgb and/or the concomitant use of
epoetin, the Normal Hematocrit Study did show a higher risk
of vascular thrombosis among those patients randomized to
the higher hematocrit group (target hematocrit of 42%,
achieved mean hematocrit of 39%). Further, from a recent
analysis of the pro-thrombotic effects of epoetin, the FDA
suggests that there is a 67% risk of thrombosis with epoetin
therapy. In a recent study, termed the SPINE study, that
evaluated patients undergoing routine orthopedic surgery,
the group treated with epoetin had a higher risk of
thromboembolic phenomenon. In the CHOIR trial, among
patients with serious adverse events, which were thought by
the investigators to be related to the study medications, a
higher rate of thromboembolic events was observed among
those assigned to the higher Hgb group.
In summary, this case highlights some of the controversies
and challenges with anemia management in dialysis patients.
The optimal target Hgb, the issue of Hgb cycling, and the
potential risks of Hgb overshoot remain problems that
nephrologists grapple with regularly. Although the clinical
implications of either Hgb cycling or Hgb overshoot are
controversial, emerging data and the recent FDA advisory
should alert clinicians with the importance of aiming for an
Hgb level less than 12 g/dl. Although epigrammatic in
approach, prudence speaks for frequent monitoring of Hgb
and altering the dose of epoetin in patients on an
individualized basis.
NOTE ADDED IN PROOF
Additional data regarding the unadjusted relative risk has been
published in Besarab A, Goodkin DA, Nissenson AR. Normal
Hematocrit Trial Authors. The normal hematocrit study-follow-up.
N Engl J Med 2008; 358: 433–434.
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